Skip to main content
SpringerLink
Log in

Prognostische Genexpressionstests

Personalisiertes Risikomanagement für das maligne Melanom

  • Dermatoonkologie
  • Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Genexpressionstests haben sich in der Tumorversorgung zu einer wertvollen Methodik entwickelt, um die Einschätzung des individuellen Rückfallrisikos zu optimieren. Auch für das maligne Melanom der Haut stehen nun derartige Tests zur Verfügung. Sie können Ärzten helfen, gemeinsam mit ihren Patienten die weitere Therapie dem individuellen Risiko anzupassen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Eggermont AMM, Robert C. New drugs in melanoma: it’s a whole new world. Eur J Cancer. 2011;47(14):2150–7.

    Article  Google Scholar 

  2. Schadendorf D, Hauschild A. Melanoma in 2013: Melanoma—the run of success continues. Nat Rev Clin Oncol. 2014;11(2):75–6.

    Article  CAS  Google Scholar 

  3. Zhu Z et al. The rapidly evolving therapies for advanced melanoma — Towards immunotherapy, molecular targeted therapy, and beyond. Crit Rev Oncol Hematol. 2016;99:91–9.

    Article  Google Scholar 

  4. Meckbach D et al. Survival according to BRAF-V600 tumor mutations — an analysis of 437 patients with primary melanoma. PLoS One. 2014;9(1):e86194.

    Article  Google Scholar 

  5. Thomas NE et al. Association Between NRAS and BRAF Mutational Status and Melanoma- Specific Survival Among Patients With Higher-Risk Primary Melanoma. JAMA Oncol. 2015;1(3):359–68.

    Article  Google Scholar 

  6. Balch CM et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.

    Article  Google Scholar 

  7. Gerami P et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21(1):175–83.

    Article  CAS  Google Scholar 

  8. http://skinmelanoma.com/decisiondx-melanoma-test/understanding-the-results/

  9. Brunner G et al. Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients. Cancer Biother Radiopharm. 2008;23(4):451–9.

    Article  CAS  Google Scholar 

  10. Brunner G et al. A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol. 2013;139(2):249–58.

    Article  CAS  Google Scholar 

  11. Brunner G et al. Independent validation of a prognostic gene-signature based risk score in formalin-fixed paraffin-embedded melanomas. Cancer Res. 2014;74(19 Suppl):Abstr 2861.

    Article  Google Scholar 

  12. Whiteman DC et al. More people die from thin melanomas (≤ 1 mm) than from thick melanomas (> 4 mm) in Queensland, Australia. J Invest Dermatol. 2015;135(4):1190–3.

    Article  CAS  Google Scholar 

  13. AJCC Cancer Staging Manual, 8th Edition. New York Heidelberg Dordrecht London: Springer; 2017.

  14. Morton DL et al. Final trial report of sentinel-node biopsy versus observation in melanoma. N Engl J Med. 2014;370(7):599–609.

    Article  CAS  Google Scholar 

  15. van der Ploeg AP et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol. 2011;29(16):2206–14.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatologisches Zentrum Bonn, Friedensplatz 16, 53111, Bonn, Deutschland

    Uwe Reinhold

  2. http://www.springermedizin.de

    Thomas Dirschka

Authors
  1. Uwe Reinhold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Dirschka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uwe Reinhold.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reinhold, U., Dirschka, T. Personalisiertes Risikomanagement für das maligne Melanom. Im Focus Onkologie 21, 18–20 (2018). https://doi.org/10.1007/s15015-018-3878-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-018-3878-1

Search

Navigation